✨ Free AI Report
Nykode Therapeutics ASA: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Nykode Therapeutics ASA
Company Research

Nykode Therapeutics ASA: Business Overview, Financials & Competitive Analysis

Nykode Therapeutics ASA scores 6/10 on the AskCyborg Cyborg Score (Solid). Patient capital in innovative personalized cancer vaccines and immune tolerance therapeutics with differentiated platform technology and multi-indication pipeline potential. Nykode demonstrates solid fundamentals with validated Vaccibody platform technology, multiple clinical-stage candidates with positive interim data, and strategic partnerships (Nektar). However, as a clinical-stage company with no approved products, it.

What is Nykode Therapeutics ASA's industry? Nykode Therapeutics ASA (nykode.com) operates in Biopharmaceuticals - Immunotherapy & Personalized Medicine. AskCyborg classifies Nykode Therapeutics ASA under Biopharmaceuticals - Immunotherapy & Personalized Medicine in its company registry.

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company listed on the Oslo Stock Exchange dedicated to the discovery and development of vaccines and novel immunotherapies. The company's platform is built...

6/ 10Solid

Cyborg Score thesis

Patient capital in innovative personalized cancer vaccines and immune tolerance therapeutics with differentiated platform...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Immunotherapy & Personalized Medicine
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Nykode Therapeutics ASA Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Nykode Therapeutics ASA

AskCyborg analysts argue the bull and bear cases for Nykode Therapeutics ASA across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Nykode Therapeutics ASA OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Nykode Therapeutics ASA Overview

Pro stress-test →

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company listed on the Oslo Stock Exchange dedicated to the discovery and development of vaccines and novel immunotherapies. The company's platform is built around the Vaccibody molecule, which induces fast, strong and long-lasting immune responses with potential to treat cancer and other disease areas.

Strategic Profile

Pro stress-test →

Lead product candidates include VB10.NEO, a cancer neoantigen vaccine in phase I/IIa clinical trial, and VB10.16, a therapeutic vaccine in phase II clinical trial for HPV16-induced malignancies. The company is utilizing its APC-targeted technology to create an immune tolerance platform for potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Competitive Landscape

Pro stress-test →

Nykode competes in the personalized cancer vaccine and immunotherapy space against companies developing neoantigen and checkpoint inhibitor combination therapies. Key competitors include Moderna and BioNTech in mRNA cancer vaccines, alongside specialized neoantigen developers. Nykode's differentiation lies in its Vaccibody platform's versatility across both cancer treatment and immune tolerance indications, supported by established manufacturing infrastructure and clinical trial experience.

Industry Context

Nykode Therapeutics ASA operates in Biopharmaceuticals - Immunotherapy & Personalized Medicine.

Key facts

Founded: 2006 · Headquarters: Oslo, Norway

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Nykode Therapeutics ASA.

  • Core Vaccibody platform validated in clinical trials with proof-of-concept for both cancer vaccines and immune tolerance applications
  • VB10.NEO individualized neoantigen vaccine backed by proprietary NeoSELECT platform with USPTO patent protection through 2039
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025U.S. Patent issued for neoantigen selection method underlying VB10.NEO platform with 20-year protection
  • August 2025Q2 2025 financial results release with strategy update announced
  • +1 moreTrack every material event for Nykode Therapeutics ASA as it happens. Explore monitoring →
Get alerted when Nykode Therapeutics ASA has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

mRNA cancer vaccinesPersonalized mRNA-based cancer immunotherapies→Checkpoint inhibitor combinationsImmuno-oncology combination therapies→Neoantigen-focused platformsIndividualized tumor vaccine approaches→

Compare Nykode Therapeutics ASA with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Nykode Therapeutics ASA operates in Biopharmaceuticals - Immunotherapy & Personalized Medicine. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Immunotherapy & Personalized Medicine research →
NEW · MCP server

Ask your AI assistant about Nykode Therapeutics ASA

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Nykode Therapeutics ASA and its top competitor on Cyborg Score”
“What did Nykode Therapeutics ASA do this quarter?”
“Is Nykode Therapeutics ASA a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Nykode Therapeutics ASA do?+
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company listed on the Oslo Stock Exchange dedicated to the discovery and development of vaccines and novel immunotherapies. The company's platform is built...
What is Nykode Therapeutics ASA's Cyborg Score?+
Nykode Therapeutics ASA has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Nykode Therapeutics ASA's main competitors?+
Named competitors include mRNA cancer vaccines, Checkpoint inhibitor combinations, Neoantigen-focused platforms. The full competitive landscape is in the AskCyborg report.
How can I get the full Nykode Therapeutics ASA research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Nykode Therapeutics ASA research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Nykode Therapeutics ASA over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.